Navigation Links
Eisai Announces Change in U.S. Submission Schedule for E7389 New Drug Application
Date:1/31/2008

cell lung cancer, prostate cancer and sarcoma.

E7389 is a novel compound developed by Eisai as a new potential anti- cancer agent that suppresses the growth of microtubule which is involved in various cellular processes in the body, such as cell division. E7389 is a synthetic analog of halichondrin B, a naturally-occurring compound which was first isolated from a type of marine sponge in 1992.

Eisai has a strong commitment to the development of new oncology medicines to address the unmet medical needs of patients with cancer. Currently, seven other Eisai oncology compounds are in clinical development, in addition to E7389.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: neurology, gastrointestinal disorders and oncology/critical care. Through a global network of research facilities, manufacturing sites and marketing affiliates, Eisai actively participates in all aspects of the worldwide healthcare system.

About Eisai Corporation of North America

Eisai Corporation of North America is a wholly-owned subsidiary of Eisai Co., Ltd. and supports the activities of its operating companies in North America. These operating companies include: Eisai Research Institute of Boston, Inc., a discovery operation with strong organic chemistry capabilities; Morphotek, Inc., a biopharmaceutical company specializing in the development of therapeutic monoclonal antibodies; Eisai Medical Research Inc., a clinical development group; Eisai Inc., a commercial operation with manufacturing and marketing/sales functions; MGI PHARMA, INC., an R&D and commercial operation with manufacturing and marketing/sales functions; and Eisai Machinery U.S.A., which markets and maintains pharmaceutical manufacturing machinery.

*Accelerated Approval under Subpart H:

One of the programs within
'/>"/>

SOURCE Eisai Corporation of North America
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics and Eisai Co., Ltd. Extend Genetics Discovery Collaboration for Alzheimers Disease
2. U.S. District Court Decision About Eisais Legal Action Over Aricept ODT(R) ANDA Filing
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
5. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
6. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
7. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
8. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
9. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
10. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Brussels (PRWEB) December 22, 2014 The ... the global leader of technical training across the life ... Clinical Data Management (SCDM) to provide the organization's ... certification programs —providing access to the more than 350 ... SCDM members with 10% off when registering for a ...
(Date:12/22/2014)... 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, announced today ... of Calgary in conjunction with co-authors from Kyoto University ... the company,s ongoing clinical research using dermal sheath cup ... The paper entitled " Hair Follicle Dermal ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/22/2014)... December 22, 2014 The ... publication of original research, reviews and editorials addressing ... clinical practice, today published a provocative article exploring ... development, progression and potential treatment of prostate cancer. ... research and proposes the possibility that there could ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Contract Research Organization to Offer Pharmaceutical Clients Comprehensive ... /PRNewswire-FirstCall/ -- Waters Corporation (NYSE: ... KS) has begun offering new metabolite profiling services ... of a Waters(R) Synapt(TM) High Definition Mass Spectrometry(TM) ...
... 16 /PRNewswire-Asia/ -- Today, Filligent, the Hong Kong-,based ... anti-,infective medical face mask, the BioMask. The BioMask ... in Filligent,s anti-microbial personal care range,BioFriend(TM), to be ... Medical Devices Directive 93/42/EEC, Filligent has met the,stringent ...
... Inc. (OTC Bulletin Board: YGYB; "Yongye" or the "Company"), ... plants and animals, located in the People,s Republic of ... a conference call and webcast in which it will ... by a question and answer session in English and ...
Cached Biology Technology:XenoTech LLC Offers Drug Industry New Metabolite Profiling Services Following Acquisition of Waters Synapt HDMS System 2XenoTech LLC Offers Drug Industry New Metabolite Profiling Services Following Acquisition of Waters Synapt HDMS System 3Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask 2Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask 3Hong Kong Biotech Company, Filligent, Announces CE Certification of Its Revolutionary, Anti-Infective Medical Face Mask, the BioMask 4Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin 2Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin 3Yongye Biotechnology to Host 'Virtual Retail Road Show' to Provide Overview of the Company in English and Mandarin 4
(Date:12/17/2014)... Valencell, a leader in performance biometric data ... industry leaders such as Intel, Jabra, Atlas, and Scosche ... products. These products will be showcased at CES 2015, ... . "Our partners choose PerformTek ... – with the clinical data to back it up," ...
(Date:12/11/2014)... 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition ... report to their offering. ... the adoption of multimodal biometric systems. Multimodal biometric ... individual for verification and identification purposes. This helps ...
(Date:12/10/2014)... 2014  Wake Forest Baptist Medical Center today announced plans ... of Medicine. Funding for this $50 million capital project ... be publicly launched next summer. The ... 60 series R.J. Reynolds Tobacco Company complex, adjacent to ... immediately with plans to be ready to welcome medical ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... of history's worst infectious diseases, but there are many more ... challenges society needs to confront to unlock the future promise ... the focus of a new report by the American Academy ... has been profound. Many diseases that formerly raged unchecked ...
... prevented rat sperm stem cells from changing permanently into ... such cells to behave like embryonic stem cells, capable ... the body. , Researchers at the Cecil H. and ... Southwestern Medical Center devised methods to keep male rat ...
... you're a swordtail fish, that is. As the size ... the preference for males with asymmetrical markings, according to ... professor of biological sciences, and colleagues found that older ... than symmetrical males when offered a choice. These findings ...
Cached Biology News:Report focuses on challenges to unlocking future promise of vaccines 2Sperm stem cells closer to being like embryonic stem cells 2Sperm stem cells closer to being like embryonic stem cells 3Older female fish prefer imperfect male mates, study finds 2Older female fish prefer imperfect male mates, study finds 3
...
... SIGNETs BCIP/NBT Chromogen system ... Tetrazolium] chromogen in a single ... reacts in the presence of ... staining with minimal background noise. ...
... Covance's BCIP/NBT Chromogen system ... Tetrazolium] chromogen in a single ... reacts in the presence of ... purple staining with minimal background ...
Mouse monoclonal antibody raised against a partial recombinant VEGFB. NCBI Entrez Gene ID = VEGFB...
Biology Products: